Download PDF
Horm Metab Res 2015; 47(13): 987-993
DOI: 10.1055/s-0035-1565208
Review

Glucose Metabolism in Primary Aldosteronism

H. Remde
1   Clinical Endocrinology, Charité Campus Mitte, Berlin, Germany
,
G. Hanslik
1   Clinical Endocrinology, Charité Campus Mitte, Berlin, Germany
,
N. Rayes
2   Clinic for Surgery, Campus Virchow, Charité University Medicine Berlin, Berlin, Germany
,
M. Quinkler
3   Endocrinology in Charlottenburg, Berlin, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

In recent years, an increasing number of studies have revealed deleterious effects of aldosterone via the mineralocorticoid receptor (MR). Especially in patients with primary aldosteronism (PA) a significant higher estimated risk of developing cardiovascular comorbidities and comortalities compared to essential hypertensives was reported. As diabetes mellitus and the metabolic syndrome are one of the major contributors to cardiovascular morbidity and mortality their connection to aldosterone excess became a focus of research in PA patients. Several studies assessed the effect of PA on glucose metabolism, the prevalence of diabetes mellitus, and the effect of PA treatment on both revealing different results. Therefore, we performed an extensive literature research. This review focuses on the current knowledge of the connection between aldosterone excess, glucose homeostasis, and diabetes mellitus in patients with PA. We have highlighted this topic from a pro and contra perspective followed by a summarizing concluding remark. Additionally, we have briefly reviewed the data on possible underlying mechanisms and indicated future considerations on the possible impact of cortisol co-secretion in PA.

Key words

aldosterone - hyperaldosteronism - diabetes mellitus - hypertension - hypokalemia - glucose tolerance


Publication History

Received: 16 August 2015

Accepted: 02 November 2015

Article published online:
14 December 2015

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: A review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol 2015; 172: R191-R203
    CrossrefPubMedGoogle Scholar
  • 2 Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Review: Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001; 2: 156-169
    CrossrefPubMedGoogle Scholar
  • 3 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Montori VM. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
    CrossrefPubMedGoogle Scholar
  • 4 Meyer A, Brabant G, Behrend M. Long-term Follow-up after Adrenalectomy for Primary Aldosteronism. World J Surg 2005; 29: 155-159
    CrossrefPubMedGoogle Scholar
  • 5 Weigel M, Riester A, Hanslik G, Lang K, Willenberg HS, Endres S, Allolio B, Beuschlein F, Reincke M, Quinkler M. Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. Eur J Endocrinol 2015; 172: 443-450
    CrossrefPubMedGoogle Scholar
  • 6 Milliez P, Girerd X, Plouin P-F, Blacher J, Safar ME, Mourad J-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
    CrossrefPubMedGoogle Scholar
  • 7 Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136: 1227-1235
    CrossrefPubMedGoogle Scholar
  • 8 Steichen O, Zinzindohoué F, Plouin P-F, Amar L. Outcomes of Adrenalectomy in Patients with Unilateral Primary Aldosteronism: A Review. Horm Metab Res 2012; 44: 221-227
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F, Pessina AC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62-69
    CrossrefPubMedGoogle Scholar
  • 10 Muth A, Ragnarsson O, Johannsson G, Wängberg B. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br J Surg 2015; 102: 307-317
    CrossrefPubMedGoogle Scholar
  • 11 Rossi G-P, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008; 19: 88-90
    CrossrefPubMedGoogle Scholar
  • 12 Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in Primary Aldosteronism. Horm Metab Res 2010; 42: 429-434
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459
    CrossrefPubMedGoogle Scholar
  • 14 Ronconi V, Turchi F, Rilli S, Di Mattia D, Agostinelli L, Boscaro M, Giacchetti G. Metabolic syndrome in primary aldosteronism and essential hypertension: Relationship to adiponectin gene variants. Nutr Metab Cardiovasc Dis 2010; 20: 93-100
    CrossrefPubMedGoogle Scholar
  • 15 Fallo F, Pilon C, Urbanet R. Primary Aldosteronism and Metabolic Syndrome. Horm Metab Res 2012; 44: 208-214
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010; 33 (Suppl. 01) S62-S69
    CrossrefPubMedGoogle Scholar
  • 17 Conn JW. Hypertension, the Potassium Ion and Impaired Carbohydrate Tolerance. N Engl J Med 1965; 273: 1135-1143
    CrossrefPubMedGoogle Scholar
  • 18 Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J, Endres S. Is Primary Aldosteronism Associated with Diabetes Mellitus? Results of the German Conn’s Registry. Horm Metab Res 2010; 42: 435-439
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, Lang K, Quack I, Rump LC, Willenberg HS, Beuschlein F, Quinkler M, Hannemann A. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn Registry. Eur J Endocrinol 2015; 173: 665-675
    CrossrefPubMedGoogle Scholar
  • 20 Wu V-C, Yang S-Y, Lin J-W, Cheng B-W, Kuo C-C, Tsai C-T, Chu T-S, Huang K-H, Wang S-M, Lin Y-H, Chiang C-K, Chang H-W, Lin C-Y, Lin L-Y, Chiu J-S, Hu F-C, Chueh S-C, Ho Y-L, Liu K-L, Lin S-L, Yen R-F, Wu K-D. Kidney impairment in primary aldosteronism. Clin Chim Acta 2011; 412: 1319-1325
    CrossrefPubMedGoogle Scholar
  • 21 Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin P-F. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: A controlled cross-sectional study. Hypertension 2009; 53: 605-610
    CrossrefPubMedGoogle Scholar
  • 22 Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007; 30: 2349-2354
    CrossrefPubMedGoogle Scholar
  • 23 Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: A follow-up study. J Clin Endocrinol Metab 2006; 91: 3457-3463
    CrossrefPubMedGoogle Scholar
  • 24 Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE. A possible association between primary aldosteronism and a lower b-cell function. J Hypertens 2007; 25: 2125-2130
    CrossrefPubMedGoogle Scholar
  • 25 Fischer E, Adolf C, Pallauf A, Then C, Bidlingmaier M, Beuschlein F, Seissler J, Reincke M. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 2513-2520
    CrossrefPubMedGoogle Scholar
  • 26 Štrauch B, Widimskỳ Jr J, Šindelka G, Škrha J. Does the treatment of primary hyperaldosteronism influence glucose tolerance. Physiol Res 2003; 52: 503-506
    CrossrefPubMedGoogle Scholar
  • 27 Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007; 25: 177-186
    CrossrefPubMedGoogle Scholar
  • 28 Williams TA, Monticone S, Urbanet R, Bertello C, Giraudo G, Vettor R, Fallo F, Veglio F, Mulatero P. Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Mol Cell Endocrinol 2012; 355: 162-168
    CrossrefPubMedGoogle Scholar
  • 29 Jin HM, Zhou DC, Gu HF, Qiao QY, Fu SK, Liu XL, Pan Y. Antioxidant N -Acetylcysteine Protects Pancreatic b-Cells Against Aldosterone-Induced Oxidative Stress and Apoptosis in Female db/db Mice and Insulin-Producing MIN6 Cells. Endocrinology 2013; 154: 4068-4077
    CrossrefPubMedGoogle Scholar
  • 30 Luther JM, Luo P, Kreger MT, Brissova M, Dai C, Whitfield TT, Kim HS, Wasserman DH, Powers AC, Brown NJ. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 2011; 54: 2152-2163
    CrossrefPubMedGoogle Scholar
  • 31 Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, Ihara G, Fujita Y, Ugawa T, Kohno M. Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells. Hypertension 2007; 50: 750-755
    CrossrefPubMedGoogle Scholar
  • 32 Sherajee SJ, Fujita Y, Rafiq K, Nakano D, Mori H, Masaki T, Hara T, Kohno M, Nishiyama A, Hitomi H. Aldosterone Induces Vascular Insulin Resistance by Increasing Insulin-Like Growth Factor-1 Receptor and Hybrid Receptor. Arterioscler Thromb Vasc Biol 2012; 32: 257-263
    CrossrefPubMedGoogle Scholar
  • 33 Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol 2014; 34: 355-364
    CrossrefPubMedGoogle Scholar
  • 34 Selvaraj J, Sathish S, Mayilvanan C, Balasubramanian K. Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat. Mol Cell Biochem 2013; 372: 113-126
    CrossrefPubMedGoogle Scholar
  • 35 Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T. Aldosterone Inhibits Insulin-Induced Glucose Uptake by Degradation of Insulin Receptor Substrate (IRS) 1 and IRS2 via a Reactive Oxygen Species-Mediated Pathway in 3T3-L1 Adipocytes. Endocrinology 2009; 150: 1662-1669
    CrossrefPubMedGoogle Scholar
  • 36 Selvaraj J, Muthusamy T, Srinivasan C, Balasubramanian K. Impact of excess aldosterone on glucose homeostasis in adult male rat. Clin Chim Acta 2009; 407: 51-57
    CrossrefPubMedGoogle Scholar
  • 37 Yamashita R, Kikuchi T, Mori Y, Aoki K, Kaburagi Y, Yasuda K, Sekihara H. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J 2014; 51: 243-251
    CrossrefPubMedGoogle Scholar
  • 38 Liu G, Grifman M, Keily B, Chatterton JE, Staal F-W, Li Q-X. Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production. Biochem Biophys Res Commun 2006; 342: 1291-1296
    CrossrefPubMedGoogle Scholar
  • 39 Widimskỳ Jr J, Strauch B, Šindelka G, Skrha J. Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus. Physiol Res 2001; 50: 603-607
    PubMedGoogle Scholar
  • 40 Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansen K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S. for the LIFE study group . Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886
    CrossrefPubMedGoogle Scholar
  • 41 Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-912
    CrossrefPubMedGoogle Scholar
  • 42 Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007; 50: 2239-2244
    Google Scholar
  • 43 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol-Gastrointest Liver Physiol 1979; 237: G214-G23
    PubMedGoogle Scholar
  • 44 Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895-906
    CrossrefPubMedGoogle Scholar
  • 45 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
    Google Scholar
  • 46 Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410
    CrossrefPubMedGoogle Scholar
  • 47 Škrha J, Haas T, Šindelka G, Prázný M, Widimský J, Cibula D, Svačina Š. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004; 89: 135-141
    CrossrefPubMedGoogle Scholar
  • 48 Ahrén B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004; 150: 97-104
    CrossrefPubMedGoogle Scholar
  • 49 Ishimori M, Takeda N, Okumura S, Murai T, Inouye H, Yasuda K. Increased insulin sensitivity in patients with aldosterone producing adenoma. Clin Endocrinol (Oxf) 1994; 41: 433-438
    CrossrefPubMedGoogle Scholar
  • 50 Garg R, Kneen L, Williams GH, Adler GK. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab 2014; 16: 268-272
    CrossrefPubMedGoogle Scholar
  • 51 Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103: 137-149
    CrossrefPubMedGoogle Scholar
  • 52 Gorden P. Glucose intolerance with hypokalemia: Failure of short-term potassium depletion in normal subjects to reproduce the glucose and insulin abnormalities of clinical hypokalemia. Diabetes 1973; 22: 544-551
    CrossrefPubMedGoogle Scholar
  • 53 Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D, Andres R. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32: 106-111
    CrossrefPubMedGoogle Scholar
  • 54 Chatterjee R, Yeh H-C, Edelman D, Brancati F. Potassium and risk of Type 2 diabetes. Expert Rev Endocrinol Metab 2011; 6: 665-672
    CrossrefPubMedGoogle Scholar
  • 55 Chatterjee R, Yeh H-C, Shafi T, Selvin E, Anderson C, Pankow JS, Miller E, Brancati F. Serum and dietary potassium and risk of incident type 2 diabetes mellitus: The atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2010; 170: 1745-1751
    CrossrefPubMedGoogle Scholar
  • 56 Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 2006; 48: 219-224
    CrossrefPubMedGoogle Scholar
  • 57 Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids 2014; 91: 54-60
    CrossrefPubMedGoogle Scholar
  • 58 Bruder-Nascimento T, da Silva MA, Tostes RC. The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetol Metab Syndr 2014; 6: 1-8
    CrossrefPubMedGoogle Scholar
  • 59 Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: An early contributor to diabetes-related vascular disease?. Diabetes 2013; 62: 313-319
    CrossrefPubMedGoogle Scholar
  • 60 Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261
    CrossrefPubMedGoogle Scholar
  • 61 Campión J, Lahera V, Cachofeiro V, Maestro B, Dávila N, del Carmen Carranza M, Calle C. In vivo tissue specific modulation of rat insulin receptor gene expression in an experimental model of mineralocorticoid excess. Mol Cell Biochem 1998; 185: 177-182
    CrossrefPubMedGoogle Scholar
  • 62 Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, Koya D, Tsuneki H, Sasaoka T. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010; 151: 2040-2049
    CrossrefPubMedGoogle Scholar
  • 63 Hogan MJ, Schambelan M, Biglieri EG. Concurrent hypercortisolism and hypermineralocorticoidism. Am J Med 1977; 62: A86
    CrossrefPubMedGoogle Scholar
  • 64 Spath M, Korovkin S, Antke C, Anlauf M, Willenberg HS. Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol 2011; 164: 447-455
    CrossrefPubMedGoogle Scholar
  • 65 Adachi J, Hirai Y, Terui K, Nakano T, Fukuda Y, Suda T, Sasano H. A report of 7 cases of adrenal tumors secreting both cortisol and aldosterone. Intern Med 2003; 42: 714-718
    CrossrefPubMedGoogle Scholar
  • 66 Suzuki J, Otsuka F, Inagaki K, Otani H, Miyoshi T, Terasaka T, Ogura T, Omori M, Nasu Y, Makino H. Primary aldosteronism caused by a unilateral adrenal adenoma accompanied by autonomous cortisol secretion. Hypertens Res 2007; 30: 367-373
    CrossrefPubMedGoogle Scholar
  • 67 Willenberg HS, Späth M, Maser-Gluth C, Engers R, Anlauf M, Dekomien G, Schott M, Schinner S, Cupisti K, Scherbaum WA. Sporadic solitary aldosterone-and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism. Hypertens Res 2010; 33: 467-472
    CrossrefPubMedGoogle Scholar
  • 68 Fujimoto K, Honjo S, Tatsuoka H, Hamamoto Y, Kawasaki Y, Matsuoka A, Ikeda H, Wada Y, Sasano H, Koshiyama H. Primary aldosteronism associated with subclinical Cushing syndrome. J Endocrinol Invest. 2013; 36: 564-567
    PubMedGoogle Scholar
  • 69 Hiraishi K, Yoshimoto T, Tsuchiya K, Minami I, Doi M, Izumiyama H, Sasano H, Hirata Y. Clinicopathological features of primary aldosteronism associated with subclinical Cushing’s syndrome. Endocr J 2011; 58: 543-551
    CrossrefPubMedGoogle Scholar
  • 70 Mazziotti G, Gazzaruso C, Giustina A. Diabetes in cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011; 22: 499-506
    CrossrefPubMedGoogle Scholar
  • 71 Ferrau F, Korbonits M. Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 2015; 173: M133-M157
    CrossrefPubMedGoogle Scholar
  • 72 Feelders RA, Pulgar SJ, Kempel A, Pereira AM. Management of Endocrine Disease: The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012; 167: 311-326
    CrossrefPubMedGoogle Scholar
  • 73 Conzo G, Pasquali D, Gambardella C, Della Pietra C, Esposito D, Napolitano S, Tartaglia E, Mauriello C, Thomas G, Pezzolla A, De Bellis A, Santini L, Sinisi AA. Long-term outcomes of laparoscopic adrenalectomy for Cushing disease. 2014 Spring Conf Ital Soc Endocr Surg – Ther Strateg Endocr Surg 2014; 12 (Suppl. 01) S107-S111
    PubMedGoogle Scholar
  • 74 Giordano R, Guaraldi F, Berardelli R, Karamouzis I, D’Angelo V, Marinazzo E, Picu A, Ghigo E, Arvat E. Glucose metabolism in patients with subclinical Cushing’s syndrome. Endocrine 2012; 41: 415-243
    CrossrefPubMedGoogle Scholar